Reference priceRUB ₽57,750.00Original source price: INR 52,500.00. Converted estimates are available by currency selection.
| Brand | Danziten |
|---|---|
| Manufacturer | Azurity Pharmaceuticals, Inc |
| Prescription required | Yes |
Danziten 71mg Tablets 14 x 2(nilotinib)
nilotinib
Description
Danziten 71mg Tablets 14 x 2(nilotinib) is a medicine catalog record in the MediPriceHub database. Active ingredient: nilotinib. Clinical use summary: See the Benefits field on this page for the product-specific indication or intended use. That field is kept separate from catalog metadata so users can distinguish clinical information from packaging information. Manufacturer or supplier: Azurity Pharmaceuticals,Inc. Therapeutic category: Medicine Library > Oncology Medicines > Leukemia Medicines. Pack information: 71 14 x 2. Origin country or market: United States. This page is for medicine catalog reference only and should be read together with the approved prescribing information in the patient or buyer's country.Benefits
DANZITEN is a kinase inhibitor indicated for the treatment of: • Adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. • Adult patients with chronic phase (CP) and accelerated phase (AP) Ph+ CML resistant to or intolerant to prior therapy that included imatinib.How to Use
Use nilotinib under the supervision of a qualified healthcare professional. Take it by mouth only according to the approved label and the dose prescribed by a qualified healthcare professional. Do not start, stop, change the dose, split or crush a dosage form, mix with other medicines, or repeat a course unless the approved product information or a clinician confirms that it is appropriate. Check the local prescribing information for age limits, dose adjustments, missed-dose instructions, storage after opening or reconstitution, and monitoring requirements.Specification
Active ingredient: nilotinib. Pack size: 71 14 x 2. Pack unit: box. Manufacturer: Azurity Pharmaceuticals,Inc. Origin country: United States. Source category: Medicine Library > Oncology Medicines > Leukemia Medicines. Availability, prescription status, storage, and exact approved use may vary by country. Check the local product information before clinical or procurement decisions.Side Effects
The available source record does not provide a clean, product-specific adverse-reaction list. Potential risks depend on the active ingredient, dose, route, treatment duration, and patient condition. Check the approved local prescribing information for the complete adverse-reaction profile, warnings, contraindications, and monitoring requirements. Seek urgent medical care for severe allergic symptoms, breathing difficulty, fainting, severe skin reactions, chest pain, serious bleeding, or rapidly worsening symptoms.Эта информация носит справочный характер. Перед применением лекарства проконсультируйтесь с медицинским специалистом.